-
公开(公告)号：US20200165344A1
公开(公告)日：2020-05-28
申请号：US16635079
申请日：2018-07-31
Applicant: DRAGONFLY THERAPEUTICS, INC.
Inventor： Gregory P. CHANG , Ann F. CHEUNG , William HANEY , Bradley M. LUNDE , Bianka PRINZ
Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor-associated antigen FLT3 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
-
公开(公告)号：US20200157226A1
公开(公告)日：2020-05-21
申请号：US16615231
申请日：2018-05-23
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Gregory P. Chang , Ann F. Cheung , William Haney , Bradley M. Lunde , Bianka Prinz
Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD16, and 5T4, a tumor-associated antigen selected from 5T4, GPNMB, FR-alpha, PAPP-A, and GPC3 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
-
公开(公告)号：US12157771B2
公开(公告)日：2024-12-03
申请号：US17308691
申请日：2021-05-05
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Hemanta Baruah , Gregory P. Chang , Ann F. Cheung , Daniel Fallon , Asya Grinberg , Zong Sean Juo , Christopher Ryan Morgan
Abstract: Described herein are multispecific binding proteins that bind NKG2D receptor, CD16, and CLEC12A, pharmaceutical compositions comprising the multispecific binding proteins, and therapeutic methods useful for the treatment of cancer.
-
公开(公告)号：US12129300B2
公开(公告)日：2024-10-29
申请号：US18501419
申请日：2023-11-03
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Gregory P. Chang , Ann F. Cheung , Asya Grinberg , William Haney , Bradley M. Lunde , Bianka Prinz
CPC classification number: C07K16/2851 , C07K16/2803 , C07K16/283 , C07K16/32 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/92 , C07K2317/94
Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
-
公开(公告)号：US20240228628A9
公开(公告)日：2024-07-11
申请号：US17769257
申请日：2020-10-14
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Hemanta Baruah , Gregory P. Chang , Ann F. Cheung , Asya Grinberg , Zong Sean Juo , Thomas J. McQuade
CPC classification number: C07K16/2863 , A61P35/02 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting FLT3 on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.
-
公开(公告)号：US20240076384A1
公开(公告)日：2024-03-07
申请号：US18501413
申请日：2023-11-03
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Gregory P. Chang , Ann F. Cheung , Asya Grinberg , William Haney , Bradley M. Lunde , Bianka Prinz
CPC classification number: C07K16/2851 , C07K16/2803 , C07K16/283 , C07K16/32 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/92 , C07K2317/94
Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
-
公开(公告)号：US20240067735A1
公开(公告)日：2024-02-29
申请号：US18501419
申请日：2023-11-03
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Gregory P. Chang , Ann F. Cheung , Asya Grinberg , William Haney , Bradley M. Lunde , Bianka Prinz
CPC classification number: C07K16/2851 , C07K16/2803 , C07K16/283 , C07K16/32 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/92 , C07K2317/94
Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
-
48.发明公开
公开(公告)号：US20230416402A1
公开(公告)日：2023-12-28
申请号：US18177847
申请日：2023-03-03
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Jean-Marie Cuillerot , Mark DeRose , Christopher Ryan Morgan , Michael C. Naill , Avni Shah
IPC: C07K16/32 , C07K16/28 , A61K31/337 , A61K39/395 , A61P35/00
CPC classification number: C07K16/32 , C07K16/2851 , C07K16/283 , C07K16/2818 , A61K31/337 , A61K39/3955 , A61P35/00 , C07K2317/622
Abstract: This disclosure relates to methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen such as HER2, and pharmaceutical compositions thereof. Also provided are uses of the multi-specific binding protein in combination with an anti-PD-1 therapeutic and/or cytoskeletal disrupting chemotherapeutic agent.
-
公开(公告)号：US20230279121A1
公开(公告)日：2023-09-07
申请号：US18040501
申请日：2021-08-05
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Asya Grinberg , Zong Sean Juo , Katia Liharska , Christopher Ryan Morgan
CPC classification number: C07K16/2863 , C12N15/63 , A61P35/00 , C07K2317/565 , C07K2317/92
Abstract: Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting EGFR on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.
-
公开(公告)号：US20230257467A1
公开(公告)日：2023-08-17
申请号：US18003308
申请日：2021-08-05
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Ann F. Cheung , Stacey V. Drabic , Asya Grinberg , Zong Sean Juo , Katia Liharska , Christopher Ryan Morgan , Nicolai Wagtmann
CPC classification number: C07K16/2851 , A61P35/00 , C07K16/283 , C07K16/2863 , C07K2317/55 , C07K2317/92 , C07K2317/524 , C07K2317/565 , C07K2317/622
Abstract: Described herein are multispecific binding proteins that bind NKG2D receptor, CD 16, and EGFR, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
